BACKGROUND: We investigated the influence of killer cell immunoglobulin-like receptor (KIR) genes, based on the genotypes of inhibitory or activating KIR, in stem cell recipients with acute myelogenous leukemia and their human leukocyte antigen-matched sibling donors on acute graft-versus host disease (GVHD) after hematopoietic stem cell transplantation. METHODS: We studied 53 consecutive donor-recipient pairs to determine the impact of KIR genotypes and their bidirectional KIR interactions. RESULTS: All activating KIR genes in donors were important factors for determining outcome in a manner distinctive for each gene studied. Specifically, the 2DS2 gene and the 2DS4*003 allele were closely correlated with acute GVHD. The 2DS1 gene was associated with a better long-term survival, even if present only in the donor and not the recipient. The 2DS3-2DS5 dual genes were more often involved in a variety of transplant-related complications. CONCLUSIONS: In conclusion, these factors may help predict transplant outcomes and aid in our understanding of immunogenetic specificity.
BACKGROUND: We investigated the influence of killer cell immunoglobulin-like receptor (KIR) genes, based on the genotypes of inhibitory or activating KIR, in stem cell recipients with acute myelogenous leukemia and their human leukocyte antigen-matched sibling donors on acute graft-versus host disease (GVHD) after hematopoietic stem cell transplantation. METHODS: We studied 53 consecutive donor-recipient pairs to determine the impact of KIR genotypes and their bidirectional KIR interactions. RESULTS: All activating KIR genes in donors were important factors for determining outcome in a manner distinctive for each gene studied. Specifically, the 2DS2 gene and the 2DS4*003 allele were closely correlated with acute GVHD. The 2DS1 gene was associated with a better long-term survival, even if present only in the donor and not the recipient. The 2DS3-2DS5 dual genes were more often involved in a variety of transplant-related complications. CONCLUSIONS: In conclusion, these factors may help predict transplant outcomes and aid in our understanding of immunogenetic specificity.
Authors: Joy Hsu; Jonathan J Hodgins; Malvika Marathe; Chris J Nicolai; Marie-Claude Bourgeois-Daigneault; Troy N Trevino; Camillia S Azimi; Amit K Scheer; Haley E Randolph; Thornton W Thompson; Lily Zhang; Alexandre Iannello; Nikhita Mathur; Karen E Jardine; Georgia A Kirn; John C Bell; Michael W McBurney; David H Raulet; Michele Ardolino Journal: J Clin Invest Date: 2018-09-10 Impact factor: 14.808
Authors: Nirali N Shah; Kristin Baird; Cynthia P Delbrook; Thomas A Fleisher; Mark E Kohler; Shakuntala Rampertaap; Kimberly Lemberg; Carolyn K Hurley; David E Kleiner; Melinda S Merchant; Stefania Pittaluga; Marianna Sabatino; David F Stroncek; Alan S Wayne; Hua Zhang; Terry J Fry; Crystal L Mackall Journal: Blood Date: 2014-12-01 Impact factor: 22.113
Authors: B M Triplett; E M Horwitz; R Iyengar; V Turner; M S Holladay; K Gan; F G Behm; W Leung Journal: Leukemia Date: 2009-02-12 Impact factor: 11.528